Clearside Biomedical, Inc. (NASDAQ:CLSD) Insider Purchases $36,500.00 in Stock

Clearside Biomedical, Inc. (NASDAQ:CLSD - Get Free Report) insider Ngai Hang Victor Chong purchased 36,500 shares of Clearside Biomedical stock in a transaction that occurred on Friday, November 1st. The stock was purchased at an average cost of $1.00 per share, for a total transaction of $36,500.00. Following the completion of the purchase, the insider now owns 100,000 shares of the company's stock, valued at $100,000. This trade represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website.

Clearside Biomedical Stock Performance

Shares of NASDAQ:CLSD traded up $0.02 during midday trading on Monday, reaching $1.03. 248,841 shares of the company's stock traded hands, compared to its average volume of 406,186. Clearside Biomedical, Inc. has a one year low of $0.76 and a one year high of $2.12. The stock has a 50 day moving average of $1.17 and a 200 day moving average of $1.20. The company has a market cap of $76.97 million, a price-to-earnings ratio of -2.01 and a beta of 2.33.

Clearside Biomedical (NASDAQ:CLSD - Get Free Report) last posted its earnings results on Monday, August 12th. The company reported ($0.10) earnings per share for the quarter, beating analysts' consensus estimates of ($0.14) by $0.04. The firm had revenue of $0.09 million during the quarter, compared to the consensus estimate of $0.25 million. During the same period in the prior year, the company posted ($0.15) EPS. Sell-side analysts predict that Clearside Biomedical, Inc. will post -0.56 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have recently commented on CLSD shares. Chardan Capital reissued a "buy" rating and issued a $6.00 target price on shares of Clearside Biomedical in a research note on Monday, October 14th. Needham & Company LLC increased their target price on Clearside Biomedical from $4.00 to $6.00 and gave the stock a "buy" rating in a research note on Thursday, October 10th. HC Wainwright reissued a "buy" rating and issued a $5.00 target price on shares of Clearside Biomedical in a research note on Tuesday, August 27th. Finally, StockNews.com raised Clearside Biomedical from a "sell" rating to a "hold" rating in a research note on Friday, October 18th. One analyst has rated the stock with a hold rating and six have given a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $5.17.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. SG Americas Securities LLC purchased a new stake in shares of Clearside Biomedical during the first quarter worth about $49,000. XTX Topco Ltd boosted its holdings in shares of Clearside Biomedical by 172.2% in the 2nd quarter. XTX Topco Ltd now owns 54,313 shares of the company's stock worth $71,000 after purchasing an additional 34,359 shares during the period. Renaissance Technologies LLC boosted its holdings in shares of Clearside Biomedical by 6.6% in the 2nd quarter. Renaissance Technologies LLC now owns 582,689 shares of the company's stock worth $757,000 after purchasing an additional 35,900 shares during the period. Assenagon Asset Management S.A. purchased a new position in shares of Clearside Biomedical in the 2nd quarter worth approximately $368,000. Finally, Vanguard Group Inc. boosted its holdings in shares of Clearside Biomedical by 14.5% in the 1st quarter. Vanguard Group Inc. now owns 2,490,796 shares of the company's stock worth $3,811,000 after purchasing an additional 314,480 shares during the period. Institutional investors own 18.75% of the company's stock.

Clearside Biomedical Company Profile

Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.